When given within three hours of stroke onset in well-selected eligible patients, intravenous (IV) thrombolysis with realtime plasminogen activator (rt-PA) has become the cornerstone of hyperacute stroke therapy. This follows approvals by the US Food and Drug Administration (FDA) in 1996 and the European Medicines Agency (EMEA) in 2002.
Recanalization rates with IV thrombolysis range between 20 and 66%
(average 46% for all occlusions) depending on the occlusion site, size and consistency of the thromboembolic material, and several other factors. However, even in Finland stroke patients do not have equal opportunities for thrombolysis. For benefits to be achieved, a number needed to treat (NNTT) of seven 2 was determined, and for hazards to occur a number needed to harm (NNTH) of one in 100 3 has been calculated.
The earlier thrombolysis is given, the better the outcome; however, not all stroke patients arrive early enough and thus the current three-hour time window is often too short. In addition to making thrombolysis available for more patients, several other treatments need to be developed. A recent analysis suggested that the benefit of IV thrombolysis continues up to 4.5
hours. 4 The European Co-operative Acute Stroke Study III (ECASS III) is a multinational, controlled, randomized study in which patients are randomized to placebo or standard IV rt-PA in a time-frame of three to 4.5
hours from stroke onset. ECASSS III will bring more certainty to the question of whether patients benefit from IV thrombolysis between three and 4.5 hours after stroke. Attempts have been made to further extend the time window for IV thrombolysis with the use of modern brain imaging modalities such as diffusion-perfusion magnetic resonance imaging (MRI) and perfusion computed tomography, with promising success. These modalities may help patient selection for thrombolysis after three hours after the onset of symptoms.
Intra-arterial (IA) thrombolysis may be more effective than IV thrombolysis, especially in cases of large artery occlusions such as internal carotid, basilar, or proximal middle cerebral artery occlusions with extensive thrombus.
IA thrombolysis leads more often to recanalization compared with IV thrombolysis (63 versus 46% for all vessels) and is associated with a similar rate of intracranial hemorrhages to IV thrombolysis. 1 IA thrombolysis with pro-urokinase was beneficial even up to six hours after stroke onset in one study, 5 but it was not approved by the FDA. A combined approach of IV and IA thrombolysis in open trials has been found to be better than IV thrombolysis, with a similar hemorrhagic complication rate to IV thrombolysis alone. 6, 7 A large randomized trial is warranted.
Novel thrombolytic agents including desmoteplase, tenecteplase, and reteplase have longer half-lives, higher fibrin specificity, and a higher resistance to PA inhibitor-1. Originally isolated from vampire bat saliva, IV desmoteplase was given in randomized trials three to nine hours after stroke onset to patients with a substantial region of penumbra. The first two trials delivered promising results, 8, 9 but the most recent efficacy trial could not confirm their results. A mutant form of rt-PA, tenecteplase, was found to be safe in a small study when given IV at 0.1-0.5mg/kg within three hours of stroke onset. 10 A randomized phase IIb trial comparing three different doses of tenecteplase with standard IV rt-PA within three hours of the time window is under way. Reteplase can be administered as a bolus, and was superior to standard rt-PA in myocardial infarction. Experience with reteplase in stroke patients remains limited. Emerging Therapies in Ischemic Stroke Management
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Mechanical Recanalization
Mechanical thrombus retraction has been used as a rescue therapy for patients who do not respond to thrombolytics, or as a primary treatment for those with contraindications to thrombolytics, and may lead to higher rates of vessel patency. 
Hypothermia
Hypothermia has been proved to be neuroprotective in numerous experimental studies and hyperthermia is associated with poor outcome in clinical studies.
Two randomized trials 17, 18 have shown that reducing body temperature to 32°C from 34°C for 12-24 hours in comatose survivors of cardiac arrest leads to better neurological outcomes and reduced mortality. Moderate hypothermia in stroke patients has been tried in a small patient series; 19 however, a wellcontrolled randomized trial is required. Deep hypothermia necessitates anesthesia and respiratory care with intubation and therefore has many severe complications and requires extensive resources, which are not always available.
In contrast, mild hypothermia with invasive or non-invasive systems may be accomplished in awake patients and can easily be given in stroke units. Pilot studies have shown a feasibility of mild (34-36°C) and moderate (32-34°C) hypothermia in stroke. Randomized studies are ongoing to prove whether mild or moderate hypothermia is beneficial in acute stroke patients. up to 48 hours after stroke onset. When the results of these three studies were pooled, they revealed a reduced death rate and improved functional recovery without increasing the proportion of severely disabled patients. 20 Decompressive craniectomy is already in use in comprehensive stroke centers.
Craniectomy

Blood-pressure-increasing/-decreasing Treatments
Induced hypertension may increase cerebral perfusion in penumbral regions and alleviate ischemic injury. Induced hypertension by means of drugs Cilexetil Therapy in Stroke Survivors (ACCESS) Study the treatment to reduce blood pressure had a positive effect on the outcome. 22 Further trials in which blood pressure is reduced to improve the outcome of patients are under way.
Neuroprotective Treatments
Neuroprotective therapy is appealing because neuroprotective agents can be safely started without a brain scan even in an ambulance and can be combined 
Brain Plasticity and Stem Cell Therapy
In experimental stroke, it has been known for a while that a brain damaged by stroke has the capacity to recover using its own or transplanted neural stem cells. This is one of the most exciting frontiers in stroke research, if not the most interesting emerging therapy for stroke. 25, 26 Bone marrow stem cells and drugs such as statins and phosphodiesterase inhibitors can induce neurogenesis from endogenous stem cells and promote functional recovery after experimental stroke. [27] [28] [29] It is hard to predict when stem cell therapies will become part of the 
Key Associations Back STOP Stroke Bill
The American Stroke Association is leading the effort to campaign to enact legislation that could ensure current and future stroke patients receive high-quality, appropriate stroke care.
The Stroke Treatment and Ongoing Prevention Act (STOP Stroke Act) seeks to ensure that stroke is more widely recognized and treated via the initiation of key actions:
• a grant program to help states ensure that patients have access to quality stroke prevention, treatment, and rehabilitation services; • a national public awareness campaign to educate the public about stroke warning signs and how stroke can be prevented; • the Coverdell Stroke Registry and Clearinghouse to collect data and share best practices; and • a grant program to educate medical professionals in newly developed diagnostic approaches, technologies, and therapies. 
